Home / News / India News / Article /
Submit immunogenicity data, SEC asks Dr Reddy before nod for Sputnik V
Updated On: 25 February, 2021 09:33 AM IST | New Delhi | IANS
Meanwhile, the committee has also asked Hyderabad-based Bharat Biotech to submit efficacy data of Covaxin before seeking its trial on children.

Delivery of supplies of the Russian Sputnik V at the State hospital in Cailungo, San Marino. Pic/AFP
The Central Drug Standard Control Organisation's (CDSCO)Subject Expert Committee has asked Dr Reddy's Laboratories to present additional data of immunogenicity while reviewing its application for Emergency Use Authorisation (EUA) of Russian Covid vaccine Sputnik V in India, sources said.
Dr Reddy's had applied for EUA before the CDSCO, and its application was reviewed by the SEC on Wednesday, a source told IANS. Meanwhile, the committee has also asked Hyderabad-based Bharat Biotech to submit efficacy data of Covaxin before seeking its trial on children. The firm had sought permission from the Drug Controller General of India to conduct vaccine's trial on the children.
How do you like the new new mid-day.com experience? Share your feedback and help us improve.

